Discover how the new McDonald criteria use imaging biomarkers such as the Central Vein Sign (CVS) to make earlier, more accurate MS diagnosis
Learn how QMENTA simplifies central vein detection in Multiple Sclerosis. Our solution automates protocol adherence, sequence recognition, and white...
Discover how the Central Vein Sign (CVS) — with 95% sensitivity and 92% specificity — is transforming MS diagnosis and how QMENTA powered the CAVS-MS...
Compare 6 automated white matter lesion segmentation tools for MS available on QMENTA — including LST-LPA, mediaire Lesion Characterization, SAMSEG,...
A history of multiple sclerosis clinical trials and drug development, from Charcot’s 1868 description to modern DMT approvals and MRI biomarkers.
Compare the top 4 open-source brain morphometry tools — FreeSurfer, FastSurfer, ANTs, and SIENA (FSL) — for cortical thickness, volumetry, and brain...
QMENTA’s AI Platform Selected for the CAVS-MS Multiple Sclerosis Biomarker...
A new article detailing how COVID-19 effects people with MS,outlining potential risks and recommendations for people with Multiple sclerosis.
#ConquerCovid, a collaborative, time-sensitive initiative designed to help the global medical community fight the COVID-19 pandemic.